AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

30/09 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
11/26/11	€0.7300	+3.55%	3,18,136
10/26/10	€0.7050	-0.14%	56,554
09/26/09	€0.7060	-3.55%	2,10,761
08/26/08	€0.7320	+0.97%	2,34,666
07/26/07	€0.7250	-0.96%	2,22,035

Real-time Euronext Paris

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris 09:25:00 11/09/2026 pm IST			5-day change	1st Jan Change
0.7300 ^EUR	+3.55%		-0.27%	-52.47%

11/09	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
17/08	AB Science completes settlement and delivery of its private placement

Market Cap	5.84Cr 6.78Cr 5.53Cr 5.01Cr 9.4Cr 647.67Cr 9.45Cr 66Cr 25Cr 329.5Cr 25Cr 25Cr 1.04TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.84Cr 6.78Cr 5.53Cr 5.01Cr 9.4Cr 647.67Cr 9.45Cr 66Cr 25Cr 329.5Cr 25Cr 25Cr 1.04TCr	EV / Sales 2026 *	48.7x	EV / Sales 2027 *	44.9x
Free-Float	69.03%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	AB	Real-time
Börse Stuttgart	A8D	Delayed
London S.E.	0Q77	Delayed
CBOE	ABp	Real-time
Deutsche Boerse AG	A8D	Delayed
CBOE	0Q77	Real-time
Tradegate	A8D	Real-time
Boerse Muenchen	A8D	Real-time

11/09	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
17/08	AB Science completes settlement and delivery of its private placement
10/08	AB Science Wraps Up EUR14 Million Private Placements	MT
10/08	AB Science raises €14.2m
13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
10/07	AB Science streamlines its portfolio and refocuses on two molecules
10/07	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
08/07	Stéphane Ledermann takes the helm at AB Science as CEO
07/07	AB Science S.A. Announces Board Changes	CI
07/07	AB Science S.A. Announces CEO Changes	CI
03/07	AB Science S.A. announced that it has received $2.01616 million in funding	CI
01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI

AB Science Share Price

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation : AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript : AB Science

Press Releases : AB Science

News in other languages : AB Science

Quotes and Performance

Price Extremes

Managers and Directors : AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

17/08	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
10/08	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
04/08	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
10/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU

24/08	AB Science : Franchissement de seuils et déclaration d'intention
17/08	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
17/08	AB Science procède au règlement-livraison de son placement privé
17/08	AB Science : annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
17/08	AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026

1 day	+3.55%
1 week	-0.27%
Current month	+3.84%
1 month	-5.32%
3 months	-17.79%
6 months	-42.61%
Current year	-52.47%

1 week	0.69	0.75
1 month	0.66	0.78
Current year	0.5	1.61
1 year	0.5	1.68
3 years	0.5	4.46
5 years	0.5	14.53
10 years	0.5	21.75

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Stéphane Ledermann CHM	Chairman	-	07/07/2026
Patrick Moussy BRD	Director/Board Member	-	20/09/2011

Date	Insider	Type	Main position	Quantity	% Market Cap.
20/05/26	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
09/02/21	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
02/02/21	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+3.55%	-0.27%	-41.13%	-74.43%	6.56Cr
MERCK & CO., INC.	-0.54%	-4.26%	+69.03%	+32.53%	36TCr
MERCK KGAA	-0.15%	-3.24%	+21.83%	-20.33%	6.66TCr
HALOZYME THERAPEUTICS, INC.	+0.19%	-2.71%	+38.27%	+185.87%	1.21TCr
KYOWA KIRIN CO., LTD.	-0.66%	-8.82%	-11.70%	-16.24%	749.87Cr
SK BIOPHARMACEUTICALS CO., LTD.	-4.80%	-8.31%	-28.14%	-8.74%	485.34Cr
YUHAN CORPORATION	+0.63%	-2.46%	-33.22%	+4.34%	437.41Cr
BETTA PHARMACEUTICALS CO., LTD.	-1.24%	-6.98%	-34.91%	-13.14%	289.19Cr
SUPERNUS PHARMACEUTICALS, INC.	-0.12%	-4.34%	-10.76%	+39.83%	242.33Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-1.84%	-5.00%	-28.35%	-23.61%	193.69Cr
Average	-0.50%	-4.22%	-5.91%	+10.61%	4.6TCr
Weighted average by Cap.	-0.51%	-4.16%	+56.57%	+26.93%

	2026 *	2027 *
Net sales	12L 13.93L 11.36L 10.3L 19.32L 13Cr 19.42L 1.35Cr 51.89L 6.77Cr 52.31L 51.16L 21Cr	13L 15.09L 12.31L 11.16L 20.93L 14Cr 21.04L 1.46Cr 56.22L 7.33Cr 56.67L 55.42L 23Cr
Net income	-	-
Net Debt	-	-